Study guide
Section 12.1: Non-Sterile Compounding Regulations
Texas MPJE Pharmacy Jurisprudence Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pharmacy Law Foundations & Regulators
Section 1.1: State and Federal Regulatory Bodies Section 1.2: Structure of Texas Pharmacy Law Section 1.3: TSBP Powers and Administrative Procedures Section 1.4: Inspections, Investigations, and Discipline
2 Chapter 2: Pharmacist Licensure & Continuing Education
Section 2.1: Initial Pharmacist Licensure & Reciprocity Section 2.2: License Renewal & Continuing Education Requirements Section 2.3: Inactive Status, Reinstatement, and Administrative Changes Section 2.4: Impaired Pharmacists & Peer Review Programs
3 Chapter 3: Pharmacy Personnel & Supervision Ratios
Section 3.1: Pharmacist-in-Charge (PIC) Responsibilities and Duties Section 3.2: Pharmacy Technicians and Technician Trainees Section 3.3: Pharmacist-to-Technician Supervision Ratios Section 3.4: Duties of Supportive Personnel
4 Chapter 4: Pharmacy Permits & Facility Classifications
Section 4.1: Texas Pharmacy Permit Classes Section 4.2: Class A (Community) Operations & Facilities Section 4.3: Class C (Institutional/Hospital) Operations & Facilities Section 4.4: Central Processing (Class G) and Non-Resident (Class E)
5 Chapter 5: Prescribers & Prescription Validity
Section 5.1: Texas Prescriptive Authority Section 5.2: General Prescription Requirements Section 5.3: Out-of-State and Canadian/Mexican Prescriptions Section 5.4: Self-Prescribing & Prescribing for Family Members
6 Chapter 6: Controlled Substances Schedules & Registration
Section 6.1: Federal vs. Texas Controlled Substances Schedules Section 6.2: DEA Registration & Texas Controlled Substances Act Section 6.3: Scheduled Listed Chemical Products Section 6.4: Controlled Substance Theft or Loss Reporting
7 Chapter 7: Controlled Substances Prescriptions & Dispensing
Section 7.1: CII Prescription Requirements and Validity Section 7.2: CII Refills, Partial Fills, and Emergency Oral Dispensing Section 7.3: CIII-CV Prescription Requirements, Validity, Refills, and Partial Fills Section 7.4: Opioid 10-day Initial Supply Limit & PMP Mandatory Queries
8 Chapter 8: Prescription Monitoring Program (PMP) & Drug Abuse
Section 8.1: Texas Prescription Monitoring Program Reporting & Database Section 8.2: Naloxone Access and Standing Orders in Texas Section 8.3: Corresponding Responsibility & Red Flags of Diversion Section 8.4: Treatment of Substance Use Disorders
9 Chapter 9: Dispensing Standards & Generic Substitution
Section 9.1: Texas Generic Substitution Law Section 9.2: Patient Counseling and Drug Utilization Review Requirements Section 9.3: Prescription Labeling Requirements in Texas Section 9.4: Poison Prevention Packaging Act & Child-Resistant Containers
10 Chapter 10: Prescription Refills, Transfers & Emergency Dispensing
Section 10.1: Prescription Refill Refusal & Professional Judgment Section 10.2: Prescription Transfer Rules Section 10.3: Emergency Refills (72-hour rule & 30-day natural disaster rule) Section 10.4: Return and Reuse of Prescription Medications
11 Chapter 11: Pharmacy Operations, Security & Recordkeeping
Section 11.1: Pharmacy Security, Alarms & Delivery of Drugs in Texas Section 11.2: General Recordkeeping & Document Retention Requirements Section 11.3: Controlled Substance Inventories Section 11.4: Disposal and Destruction of Controlled Substances
12 Chapter 12: Compounding Standards (Sterile & Non-Sterile)
Section 12.1: Non-Sterile Compounding Regulations Section 12.2: Sterile Compounding Regulations Section 12.3: Hazardous Drug Handling Section 12.4: Compounding Recordkeeping & Quality Control
13 Chapter 13: Specialized Pharmacy Practice & Public Safety
Section 13.1: Collaborative Practice Agreements & Drug Therapy Management Section 13.2: Pharmacist Immunization Authority & Protocol Requirements Section 13.3: Automated Dispensing Devices (Class A, C, and remote sites) Section 13.4: Public Health Laws (HIPAA, OBRA-90, DSCSA Drug Track and Trace)
Section 12.1: Non-Sterile Compounding Regulations
Key Takeaways Explain This Topic AI
Texas non-sterile compounding is governed under TSBP Rule §291.131, which closely aligns with the national USP <795> standards.
Compounding (regulated under FDA Section 503A) must be patient-specific and is distinct from manufacturing (FDA Section 503B/registered manufacturers), which involves mass production for resale.
Under the 2023 USP <795> revisions, beyond-use dates (BUDs) are determined by the preparation's water activity (aw), classifying formulations as nonaqueous (90 days), preserved aqueous (35 days), or non-preserved aqueous (14 days refrigerated).
Texas requires all compounded prescriptions to carry a prominent label statement reading 'Compounded by Pharmacy' along with active ingredient names and strengths.
Bulk compounding in anticipation of prescriptions is permitted under TSBP rules but only in limited quantities based on historically documented local prescribing patterns.
Last updated: July 2026
Section 12.1: Non-Sterile Compounding Regulations
Non-sterile compounding is regulated in Texas by the Texas State Board of Pharmacy (TSBP) under Texas Administrative Code (TAC) Rule §291.131 , which mirrors USP Chapter <795> standards. Candidates preparing for the Texas MPJE must understand physical standards, operational rules, and beyond-use dating (BUD) principles.
Compounding vs. Manufacturing
A critical distinction under federal law and TSBP rules is the boundary between compounding and manufacturing. Under Section 503A, compounding is a customized service performed by a licensed pharmacist to meet a specific patient's needs. Under Section 503B, bulk production is classified as manufacturing:
Section 503A (Traditional Compounding): Traditional pharmacies compound preparations for individual patients based on a valid, patient-specific prescription. Under 503A, pharmacies are regulated primarily by the state board (TSBP) and are exempt from FDA Current Good Manufacturing Practices (cGMP) and pre-market approval processes. The FDA retains inspection authority but generally defers to state boards for routine oversight.
Section 503B (Outsourcing Facilities): Facilities compounding sterile preparations in bulk without patient-specific prescriptions register under 503B. They must comply with FDA cGMP, undergo FDA inspections, and may distribute compounds to practitioners for office use. In Texas, a 503B facility must hold a Class DSM pharmacy license.
Anticipatory Compounding: Under TSBP rules, community pharmacies (Class A) may compound preparations in advance of receiving a prescription, but only in limited quantities based on historical prescribing patterns (typically not exceeding a 30-day supply). Compounding bulk quantities for resale or distribution to other pharmacies without patient-specific demand is classified as manufacturing and carries severe administrative penalties.
Physical Facility and Equipment Requirements
TSBP Rule §291.131 mandates specific facility and equipment standards to ensure quality control:
Compounding Area: A designated area with adequate space must be set aside to prevent mix-ups and cross-contamination. It must be clean, well-lighted, and have accessible hand-washing facilities. The area must be separated from general dispensing areas by a barrier or partition if there is a risk of cross-contamination.
Water Quality: Purified Water, USP (or better) is required for compounding non-sterile preparations when water is a component. Potable (tap) water is acceptable only for initial washing of equipment, but the final rinse must use Purified Water, USP to prevent chemical or microbial residues.
Equipment: All equipment (balances, mortars, electronic mixers) must be clean, maintained, and calibrated. Balances must be calibrated at least annually by an qualified technician, with records kept for two years. Graduated cylinders and other measuring devices must meet appropriate class tolerances.
Ingredient Standards and the "Three-Year Receipt Rule"
Pharmacists compounding non-sterile preparations must use high-quality ingredients:
Grade: Ingredients should preferably be USP/NF grade. If unavailable, analytical reagent or Food Chemicals Codex grade may be used. Industrial-grade chemicals are prohibited.
COA: A Certificate of Analysis (COA) must be obtained and kept on file for each lot of bulk drug substances.
Expiration Dates: If an ingredient lacks a manufacturer-assigned expiration date, the pharmacist must assign a conservative date based on stability data, not to exceed three years from the date of receipt at the pharmacy. The receipt date and assigned expiration must be written on the container.
Personnel Training and Competencies
All personnel engaged in compounding—including pharmacists, technicians, and trainees—must complete initial training in hand hygiene, garbing, equipment use, and documentation. The pharmacy must perform and document an initial competency assessment. The Pharmacist-in-Charge (PIC) must maintain records of all training and annual competency assessments for compounding personnel, immediately available for TSBP inspection.
Determining Beyond-Use Dates (USP <795> Revisions)
Under the 2023 USP <795> revisions adopted by the TSBP, BUDs are determined by the formulation type and the water activity ( a w a_w a w ) of the compounded non-sterile preparation. Water activity is a measure of free water available for microbial growth. Formulations with a w < 0.6 a_w < 0.6 a w < 0.6 are nonaqueous, while those with a w ≥ 0.6 a_w \geq 0.6 a w ≥ 0.6 are aqueous.
In the absence of formulation-specific stability data, the following maximum BUD limits must be applied to preparations packaged in tight, light-resistant containers:
Formulation Type Water Activity ( a w a_w a w ) Storage Temperature Maximum Beyond-Use Date (BUD)
Nonaqueous Oral Formulations (e.g., capsules, tablets, powders) < 0.6 < 0.6 < 0.6 Controlled Room Temp or Refrigerated 90 Days
Nonaqueous Topical/Dermal (e.g., ointments, pastes) < 0.6 < 0.6 < 0.6 Controlled Room Temp or Refrigerated 90 Days
Preserved Aqueous Formulations (e.g., oral suspensions with preservatives) ≥ 0.6 \geq 0.6 ≥ 0.6 Controlled Room Temp or Refrigerated 35 Days
Non-Preserved Aqueous Formulations (e.g., suspensions without preservatives) ≥ 0.6 \geq 0.6 ≥ 0.6 Refrigerated ( 2 ∘ C 2^{\circ}\text{C} 2 ∘ C to 8 ∘ C 8^{\circ}\text{C} 8 ∘ C ) 14 Days
Commercial Product Expirations
If a compounded preparation is prepared by manipulating a commercial product (such as crushing commercial tablets), the BUD assigned cannot exceed the manufacturer's original expiration date on the commercial container if it is shorter than the maximum BUD in the table.
Texas Labeling Requirements and Exam Traps
Under TSBP §291.131, every compounded preparation dispensed to a patient must carry standard labeling information, plus:
Compounding Statement: A prominent label statement reading "Compounded by Pharmacy" .
Active Ingredients: The names and strengths of all active ingredients.
Beyond-Use Date: The clearly stated assigned BUD.
Storage Directions: Specific requirements (e.g., 'Keep Refrigerated').
MPJE Exam Trap: Flavoring
Under Texas law, adding flavoring to a commercially manufactured, FDA-approved product is classified as compounding. This requires a compounding record, assigning an appropriate BUD, and labeling the container with the statement "Compounded by Pharmacy". The pharmacist must ensure that the addition of flavoring does not compromise the stability of the drug product, and the product's original expiration date must be adjusted accordingly if it is shorter than 14 days refrigerated or 35 days room temp.